Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Figure 7

Trastuzumab caused tumor regression in BT-474 and SK-OV-3 xenografts in combination with brusatol. (a) Mean tumor volume of SK-OV-3 xenografts after injection with control IgG (15 mg/kg), trastuzumab (15 mg/kg), brusatol (2 mg/kg), or trastuzumab (15 mg/kg) plus brusatol (2 mg/kg). (b) On day 15 postfirst injection, xenograft tumors from each group were removed and tumor masses were weighed. (c) Effects of trastuzumab, brusatol or trastzuamb plus brusatol on tumor-bearing mice body weight were determined using SK-OV-3 tumor-bearing nude mice. Mice were weighed at regular intervals during the whole period to monitor unspecific toxicity. (d) Mean tumor volume of BT-474 xenografts after injection with control IgG (15 mg/kg), trastuzumab (15 mg/kg), brusatol (2 mg/kg), or trastuzumab (15 mg/kg) plus brusatol (2 mg/kg). (e) On day 17 postfirst injection, xenograft tumors from each group were removed and tumor masses were weighed. (f) Effects of trastuzumab, brusatol or trastzuamb plus brusatol on tumor-bearing mice body weight were determined using BT-474 tumor-bearing nude mice. Mice were weighed at regular intervals during the whole period to monitor unspecific toxicity. Data are shown asa . ( mice, each group); ; ; .

(a)

(b)

(c)

(d)

(e)

(f)